Analysis of the therapeutic evolution in the management of airway infantile hemangioma
| Autor: | Grecia V. Vivas-Colmenares, Jose Antonio Matute de Cardenas, Juan Carlos López-Gutiérrez, Israel Fernandez-Pineda, Miguel Angel Fernandez-Hurtado, Maria Antonia Garcia-Casillas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Fulminant Stridor Group B Sepsis 03 medical and health sciences Cushing syndrome 0302 clinical medicine immune system diseases Retrospective Study medicine 030223 otorhinolaryngology Response rate (survey) business.industry Retrospective cohort study respiratory system medicine.disease eye diseases digestive system diseases Surgery 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health sense organs medicine.symptom Airway business |
| Popis: | AIM: To analyze the evolution in the management of airway infantile hemangioma (AIH) and to report the results from 3 pediatric tertiary care institutions. METHODS: A retrospective study of patients with diagnosis of AIH and treated in 3 pediatric tertiary care institutions from 1996 to 2014 was performed. RESULTS: Twenty-three patients with diagnosis of AIH were identified. Mean age at diagnosis was 6 mo (range, 1-27). Single therapy was indicated in 16 patients and 7 patients received combined therapy. Two therapeutic groups were identified: Group A included 14 patients who were treated with steroids, interferon, laser therapy and/or surgery; group B included 9 patients treated with oral propranolol. In group A, oral corticosteroids were used in 9 patients with a good response in 3 cases (no requiring other therapeutic option), the other patients required additional treatment options. Cushing syndrome was observed in 3 patients. One patient died of a fulminant sepsis. Open surgical excision and endoscopic therapy were performed in 11 patients (in 5 of them as a single treatment) with a response rate of 54.5%. Stridor persisted in 2 cases, and one patient died during the clinical course of bronchial aspiration. In group B, oral propranolol was used in 9 patients (in 8 of them as a single treatment) with a response rate of 100%, with an mean treatment duration of 7 mo (range, 5-10); complications were not observed. CONCLUSION: Our experience and the medical literature support the use of propranolol as a first line of treatment in AIH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|